Skip to main content

Table 2 Univariate and multivariable analysis of prognostic indicators on overall survival and cancer-specific survival for 1095 colorectal cancer patients

From: Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer

Parameters Overall survival Cancer-specific survival
  Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
HRd (95 % CIe) P value HRd (95 % CIe) P value HRd (95 % CIe) P value HRd (95 % CIe) P value
Age (years) 1.352 (1.099 – 1.664) 0.002* 1.347 (1.008 – 1.801) 0.044* 1.349 (1.096 – 1.601) 0.005* 1.362 (1.018 – 1.822) 0.037*
≥65 vs <65 (576/519)
Gender 1.098 (0.893 – 1.349) 0.377 1.036 (0.795 – 1.506) 0.792 1.096 (0.891 – 1.347) 0.386 1.032 (0.792 – 1.345) 0.817
Male vs Female (619/476)
Location 1.309 (1.041 – 1.647) 0.021* 1.172 (0.870 – 1.580) 0.296 1.303 (1.036 – 1.639) 0.024* 1.168 (0.867 – 1.572) 0.308
Right vs Left (249/846)
Tumor size 1.477 (1.200 – 1.817) <0.001* 0.981 (0.745 – 1.292) 0.893 1.480 (1.203 – 1.821) <0.001* 0.979 (0.744 – 1.289) 0.880
≥5 cm vs <5 cm (466/612)
Tumor depth 2.959 (2.088 – 4.193) <0.001* 1.385 (0.596 – 3.220) 0.449 2.867 (2.094 – 4.205) <0.001* 1.379 (0.593 – 3.205) 0.455
T3 + T4 vs T1 + T2 (853/235)
Lymph Node metastasis 2.464 (1.996 – 3.042) <0.001* 1.055 (0.644 – 1.730) 0.831 2.460 (1.992 – 3.037) <0.001* 1.060 (0.647 – 1.738) 0.816
Yes vs No (452/633)
AJCCa stage 3.441 (2.753 – 4.302) <0.001* 1.375 (1.032 – 1.760) 0.015* 3.436 (2.748 – 4.295) <0.001* 2.022 (1.065-2.099) <0.001*
III + IV vs I + II (516/579)
Histology 1.997 (1.510 – 2.642) <0.001* 1.655 (1.153 – 2.275) 0.006* 2.012 (1.521 – 2.662) <0.001* 1.687 (1.177 – 2.419) 0.004*
PD vs MD + WDb (108/952)
Vascular invasion 2.796 (2.261 – 3.457) <0.001* 1.642 (1.228 – 2.149) 0.001* 2.783 (2.251 – 3.441) <0.001* 1.623 (1.226 – 2.418) 0.001*
Yes vs No (338/724)
Perineurial invasion 2.437 (1.971 – 3.013) <0.001* 1.787 (1.358 – 2.351) <0.001* 2.423 (1.960 – 2.996) <0.001* 1.765 (1.341 – 2.322) <0.001*
Yes vs No (391/673)
Pre-op CEAc (ng/ml) 3.047 (2.423 – 3.832) <0.001* 1.249 (0.902 – 1.729) 0.180 3.053 (2.428 -–3.840) <0.001* 1.245 (0.899 – 1.723) 0.186
≥5/ vs <5 (475/545)
Post-op CEA c (ng/ml) 5.567 (4.456 – 6.956) <0.001* 2.492 (1.817 – 3.418) <0.001* 5.591 (4.474 – 6.986) <0.001* 2.514 (1.832 – 3.449) <0.001*
≥5 vs <5 (266/752)
Pre-op albumin (g/dl) 1.847 (1.474 – 2.314) <0.001* 1.245 (0.933 – 1.662) 0.137 1.828 (1.460 – 2.290) <0.001* 1.221 (0.915 – 1.630) 0.175
<3.5 vs ≥3.5 (324/572)
Diabetes mellitus 1.012 (0.795 – 1.288) 0.923 0.962 (0.710 – 1.305) 0.804 1.012 (0.795 – 1.288) 0.924 0.949 (0.700 – 1.288) 0.738
Yes vs No (255/840)
Cardiac disease 1.162 (0.947 – 1.427) 0.150 1.016 (0.772 – 1.337) 0.909 1.162 (0.947 – 1.426) 0.151 1.019 (0.774 – 1.342) 0.895
Yes vs No (462/633)
Renal disease 2.583 (1.777 – 3.754) <0.001* 3.139 (1.854 – 5.317) <0.001* 2.588 (1.780 – 3.761) <0.001* 3.101 (1.830 – 5.254) <0.001*
Yes vs No (52/1043)
Chemotherapy 1.509 (1.188 – 1.916) <0.001* 1.233 (0.831 – 1.828) 0.298 1.580 (1.188 – 1.915) 0.001* 1.230 (0.830 – 1.824) 0.302
Yes vs No (731/360)
  1. aAJCC American Joint Commission on Cancer, bPD Poorly differentiated, MD Moderately differentiated, WD Well differentiated
  2. cCEA Carcinoembryonic antigen, dHR Hazard ratio, eConfidence interval
  3. *Indicated P < 0.05